Treatment of melasma in Caucasian patients using a novel 694-nm Q-switched ruby fractional laser

Said Hilton1*, Heike Heise1, Bettina Alexandra Buhren2, Holger Schrumpf2, Edwin Bölke3 and Peter Arne Gerber2*

Abstract

Background: Melasma is a common hypermelanosis of the face. The use of a classical Q-switched ruby laser (QSRL) to treat melasma is discussed controversially and is associated with frequent adverse effects, such as hyper- or hypopigmentation. Recently a fractional-mode (FRx) QSRL was developed to minimize the adverse effects of classical QSRL. The objective of this research was to evaluate the efficacy and safety of a novel FRx-QSRL in the treatment of melasma in Caucasian patients.

Methods: We performed a retrospective study of 25 Caucasian melasma patients (Fitzpatrick skin types I to III). Patients received one to three FRx-QSRL treatments (Tattoostar FRx, Asclepion Laser Technologies, Jena, Germany) at pulse energies of 4 to 8 J/cm². Three blinded investigators independently evaluated the melasma area and severity index (MAFI) score before treatment and at the four- to six-week follow-ups. At additional three-month follow-ups, patients evaluated subjective improvement, pain and over-all satisfaction with the treatment according to a numeric analogue score (NAS). Side effects were documented.

Results: At four to six weeks post laser treatment for a mean of 1.4 sessions, we observed a significant ($P = 0.0001$) reduction of the MAFI score from 6.54 to 1.98 (72.3%). Patients rated the pain of the intervention at a mean 2.46 points (0 = no pain; 10 = maximum pain), the improvement at a mean 5.55 points (0 = no improvement; 10 = maximum satisfaction) and the overall satisfaction at a mean 6.66 points (0 = not satisfied; 10 = maximum satisfaction). After three months, post-inflammatory hyperpigmentation (PIH) and/or recurring melasma were observed in 7 (28%) and 11 (44%) patients, respectively.

Conclusion: The 694-nm FRx-QSRL is a safe and effective option for treating melasma in Caucasian patients. Over periods of >3 months, PIH and/or recurring melasma may develop at significant rates and may reduce patient satisfaction. Multiple treatment sessions with lower pulse energies and/or a post-interventional therapy with hypopigmenting ointments and UV protection may help to minimize these complications.

Background

Melasma is a common acquired benign pigmented disorder that classically manifests as symmetrical hypermelanosis of the face. Most commonly melasma affects women of reproductive age with darker skin types (Fitzpatrick skin types IV and higher) but it may also occur at other ages and in men. Briefly, the Fitzpatrick skin type classification system is based on the color of the skin (type I being the fairest (white) and type VI being the darkest (black)) and its response to UV exposure (pigmentation) [1]. An estimated more than five million people are affected by melasma in the United States of America alone [2]. Melasma has a significant negative impact on a patient’s quality of life [3]. Risk factors include ultraviolet (UV) exposure, hormonal alterations (for example, pregnancy or oral contraceptives), thyroid disease and anti-seizure medication. Melasma that is related to pregnancy (or hormonal alterations) is also referred to as chloasma.

* Correspondence: info@dr-hilton.de; PeterArne.Gerber@med.uni-duesseldorf.de
1 Medical Skin Center, Düsseldorf, Germany
Full list of author information is available at the end of the article

© 2013 Hilton et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The pathogenesis of melasma has remained largely elusive. Established concepts propose a stimulation of pigment-producing cells (melanocytes) by sex hormones (estrogen and progesterone) and UV irradiation. Recent studies have reported paracrine effects amongst melanocytes, keratinocytes and/or fibroblasts [4-7], and have identified stem cell factor (SCF) and c-kit as pathogenic factors. The authors propose that UV irradiation induces SCF in dermal fibroblasts. Subsequently, the proliferation and melanogenesis of melanocytes is induced via SCF/c-kit-induced signaling [8]. Hypopigmenting topical agents containing hydroquinone, broad-spectrum UV protection and camouflaging are considered the current standard of care for treating melasma. Additional therapeutic options include topical retinoic acids (tretinoin), azelaic acid, microdermabrasion, chemical peeling or electromagnetic devices, such as lasers [9-12].

Various laser and light systems, including ruby lasers, Er:YAG lasers, carbon dioxide (CO₂) lasers and intense pulsed light (IPL), have been evaluated for their efficacy in treating melasma [12-14]. IPL therapy effectively reduced the severity of melasma in a population of 89 Asian women [15]. The use of conventional ablative laser systems (Er:YAG and CO₂) for treating melasma has been reported to be associated with a significant frequency of post-interventional hyper- as well as hypopigmentation [16,17]. The frequency of adverse effects may be limited by using novel fractional laser systems [18]. Notably, several trials studying the effects of Q-switched ruby lasers (QSRLs) have reported controversial results. In 1994, Taylor and Anderson noted that QSRLs were ineffective for treating refractory melasma and post-inflammatory hyperpigmentation [19]. A split-face study by Tse et al. demonstrated that melasma patients developed post-inflammatory hyperpigmentation (PIH) and worsening of the melasma after QSRL therapy [20]. Conversely, a recent study by Jang et al. reported that a novel fractional-mode (FRx) QSRL (TattooStar FRx, Asclepion Laser Technologies, Jena, Germany) may be effective in treating melasma in Korean patients [21].

Fractional photothermolysis has revolutionized laser resurfacing (LSR) and was initially presented by Manstein and coworkers in 2004 [22]. The significant adverse effects of classical LSR are significantly reduced by delivering the laser beam using a microarray. This technique creates microscopic columns of treated tissue and intervening areas of untreated skin, thereby allowing rapid re-epithelialization and minimal downtime. Fractional delivery has been developed for CO₂, Er:YAG, and yttrium scandium gallium garnet lasers [23]. Recently, a fractional-mode QSRL has been developed (TattooStar FRx, Asclepion Laser Technologies, Jena, Germany), which can homogenously deliver ruby laser microspots. The laser delivers a 7.1 x 7.1 mm² array of 196 microspots of 300 μm at a pulse duration of 40 ns, with an overall coverage of 27.7%. This approach may minimize the adverse effects of classical QSRL, such as PIH and hypopigmentation. Here, we present a retrospective analysis of 25 Caucasian patients, which assesses the efficacy of an FRx-QSRL in treating melasma.

Methods

Patients

In the study, 25 Caucasian women (mean age 39.8 years; range 31 to 57; Fitzpatrick skin types I to III) with melasma were treated with an FRx-QSRL (TattooStar FRx, Asclepion Laser Technologies, Jena, Germany) at the Medical Skin Center, Düsseldorf, in 2010 and 2011. Patients presented with epidermal or mixed-type melasma. Of the patients, 19 had had melasma <10 years and 6 had had it >10 years. The melasma areas were located on the forehead (n = 14), the cheeks (n = 12), the chin (n = 2) or the upper lip (n = 2). Identified risk factors included past pregnancies (n = 5), hormonal therapy (n = 12) and UV exposure (n = 25). Some patients presented with melasma in multiple locations and/or risk factors.

Treatment

We used a 694-nm FRx-QSRL (TattooStar FRx, Asclepion Laser Technologies, Jena, Germany) at fluences of 4 to 8 J/cm² and a frequency of 1 Hz. For each individual patient, the fluence was gradually increased to identify the minimal fluence needed to achieve a clinical effect (photodisruption). Each patient received laser treatment for all affected areas. In pain-sensitive patients, a topical anesthetic (a lidocaine-tetracaine mix) was applied onto the treated areas 30 minutes prior to treatment. However, most patients tolerated the intervention without anesthesia. The laser treatment lasted up to 10 minutes depending on the size and number of treated areas. Post-intervention, cool packs were applied. Patients were advised to use strict UV protection. If more than one treatment was needed, the patient received additional treatments after intervals of four weeks.

Evaluation

Photographs (Canon EOS 40D digital camera, Tokyo Japan) were taken before therapy and at the four- to six-week follow-up sessions. Three blinded investigators independently evaluated the melasma area and severity index (MASI) score before treatment and at the four- to six-week follow-ups, as previously described [24]. At the additional three-month follow-ups, patients evaluated subjective improvement, pain and their overall satisfaction with the treatment was determined according to a
numeric analogue score (NAS). At this time point, side effects were documented.

Statistical analysis
Student’s T-test was used for the statistical analysis, and \( P < 0.05 \) was regarded as statistically significant.

Results
The analysis included 25 patients. At the follow-up at four to six weeks after the last treatment (there were up to three treatment sessions with a mean of 1.4 sessions) the average MASI score showed a significant reduction from 6.54 to 1.98 (72.3%) (Figures 1 and 2). In general, the adverse effects for the first days post therapy were mild and included erythema, a burning sensation, pruritus and exfoliation. After three months, PIH and/or recurring melasma were observed in 7 (28%) and 11 (44%) patients, respectively.

The patients’ self-evaluation rated the pain of the intervention at a mean 2.46 points (0 = no pain; 10 = maximum pain), the improvement at a mean 5.55 points (0 = no improvement; 10 = maximum improvement) and the overall satisfaction at a mean 4.66 points (0 = not satisfied; 10 = maximum satisfaction). We also used the same protocol to treat patients with darker skin types and melasma and/or PIH, with satisfactory results (Figure 3).

Discussion
Laser therapy is based on the biophysical principle of selective photothermolysis. The lasers used emit light at a wavelength that is specifically and adequately absorbed by the target chromophores [25]. The target chromophore for pigmented lesions is melanin. Laser light that is adequately absorbed by melanin includes that from ruby (694 nm), Nd:YAG (523 and 1064 nm) and alexandrite (755 nm) lasers. Q-switched (QS) lasers generate a rapid burst of light, which matches the thermal relaxation time for melanin, thereby effectively destroying the pigment [14].

QS-Nd:YAG lasers have been shown to be effective and are widely used in the management of melasma [26-29]. A representative recent study by Zhou et al. of 50 patients (Fitzpatrick skin types IV to VI) demonstrated a mean decrease in the MASI score of 61.3% after nine sessions. At the three-month follow-up a
A recurrence rate of 64% was noted [29]. A study of 50 patients by Sim et al. reported improvement rates of 50% to 74% [28]. For the QSRL, earlier reports state that the laser is ineffective for melasma or may even worsen the pigmentation after therapy [19,20]. Conversely, a recent study by Jang et al. demonstrated a mean decrease of the MASI score of 29.8% in 15 Korean patients after six treatments with an FRx-QSRL (Tattoostar FRx, Asclepion Laser Technologies, Jena, Germany). Two patients reported a slight worsening. None of the patients reported any long-term adverse effects such as PIH [21]. Jang et al. found that a QSRL was more effective for treating melasma compared to a QS-Nd:YAG laser [21]. This has been demonstrated by comparative studies for other pigmented lesions, such as nevus of Ota, lentigo, PIH and Becker’s nevus, and it is proposed that this is due to the stronger absorption of the 694-nm wavelength light (QSRL) by melanin compared to 1064-nm wavelength light (QS-Nd:YAG) [20,21,30].

Consistent with the results of Jang et al., we have demonstrated a significant ($P = 0.0001$) decrease of the MASI score of 72.3% in 25 Caucasian patients after a mean of 1.4 sessions with an FRx-QSRL (Tattoostar FRx, Asclepion Laser Technologies, Jena, Germany). As the risk of common adverse effects of QSRL therapy, such as PIH, is expected to be significantly lower in Caucasian compared to Asian skin types, we applied higher fluences (4 to 8 J/cm²) per session compared to Jang et al. (2 to 3 J/cm²). However, this more aggressive treatment resulted in a significantly higher rate of adverse effects (PIH and/or recurring melasma in 28% and 44% of the patients). Lower fluences and multiple treatment sessions may reduce the frequency of these adverse effects. However, many patients refuse further treatment (and want to avoid additional costs) if the result of an initial treatment is minimal. An additional option could be a multimodal therapy using an FRx-QSRL in combination with microdermabrasion [27], chemical peeling [31] and/or hypopigmenting topical agents [32].

**Conclusions**

In summary, the FRx-QSRL is a safe and effective treatment for melasma for patients with Caucasian or Asian skin types. Multimodal concepts may further increase the efficacy and reduce the adverse effects of the therapy. We maintained only a three-month follow-up after the final treatment, so further long-term studies are needed.

**Consent**

Written informed consent was obtained from the patients for the publication of this report and any accompanying images.
Abbreviations
FFr: Fractional-mode; IPL: Intense pulsed light; LSR: Laser resurfacing; MASI: Melasma area and severity index; PIH: Post-inflammatory hyperpigmentation; QS: Q-switched; QSRIL: Q-switched ruby laser; SCF: Stem cell factor.

Competing interests
PA Gerber received honoraria for oral presentations by Asclepion Laser Technologies.

Authors’ contributions
SH and HH performed the laser treatments and collected the data. BAB, HS, EB and PAG evaluated and analyzed the data, and wrote the manuscript. All authors read and approved the final manuscript.

Author details
1Medical Skin Center, Düsseldorf, Germany. 2Departments of Dermatology, University of Düsseldorf, Düsseldorf, Germany. Radiation Oncology, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany.

Received: 11 July 2013 Accepted: 29 October 2013

Published: 14 November 2013

References
1. Taylor SC, Cook-Bolden F: Defining skin of color. Cutis 2002, 69:435–437.
2. Grimes PE: Melasma. Etiologic and therapeutic considerations. Arch Dermatol 1995, 131:1453–1457.
3. Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, Feldman SR, Chen MM: Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol 2003, 149:572–577.
4. Imokawa G, Yada Y, Miyagishi M: Endothelins secreted from human keratinocytes are important mitogens for human melanocytes. J Biol Chem 1992, 267:24675–24680.
5. Imokawa G, Yada Y, Morisaki N, Kimura M: Biological characterization of human fibroblast-derived mitogenic factors for human melanocytes. Biochem J 1998, 330(Pt 3):1235–1239.
6. Kang HY, Choi YM: FK506 increases pigmentation and migration of human melanocytes. Br J Dermatol 2006, 155:1037–1040.
7. Schauer E, Trautinger F, Kock A, Schwarz A, Bhardwaj R, Simon M, Ansel JC, Schwarz T, Luger TA: Propiomelanocortin-derived peptides are synthesized and released by human keratinocytes. J Clin Invest 1994, 93:2258–2262.
8. Kang HY, Hwang JS, Lee JY, Ahn JH, Kim JY, Lee ES, Kang WH: The dermal stem cell factor and c-kit are overexpressed in melasma. Br J Dermatol 2006, 154:1094–1099.
9. Ball Arefiev KL, Hantash BM: Advances in the treatment of melasma: a review of the recent literature. Dermatol Surg 2012, 38:971–984.
10. Sehgal VN, Verma P, Srivastava G, Aggarwal AK, Verma S: Melasma: treatment strategy. J Cosmet Laser Ther 2011, 13:265–279.
11. Sheth VM, Pandya AG: Melasma: a comprehensive update: part I. J Am Acad Dermatol 2011, 65:889–897, quiz 698.
12. Sheth VM, Pandya AG: Melasma: a comprehensive update: part II. J Am Acad Dermatol 2011, 65:699–714, quiz 715.
13. Alster TS, Lupton JR: Lasers in dermatology. An overview of types and indications. Ann J Clin Dermatol 2001, 2:291–303.
14. Polder KD, Landau JM, Vergills-Kalner U, Goldberg LH, Friedman PM, Bruce S: Laser eradication of pigmented lesions: a review. Dermatol Surg 2011, 37:572–595.
15. Li YH, Wu Y, Chen JZ, Gao XH, Liu M, Shu CM, Dong GH, Chen HD: Application of a new intense pulsed light device in the treatment of photoaging skin in Asian patients. Dermatol Surg 2008, 34:1459–1464.
16. Angsuarangsee S, Polnikom N: Combined ultrapulse CO2 laser and Q-switched alexandrite laser compared with Q-switched alexandrite laser alone for refractory melasma: split-face design. Dermatol Surg 2003, 29:69–64.
17. Manaloto RM, Alster T: Erbium:YAG laser resurfacing for refractory melasma. Dermatol Surg 1999, 25:121–123.
18. Rohksar CK, Fitzpatrick RE: The treatment of melasma with fractional photothermolysis: a pilot study. Dermatol Surg 2005, 31:1645–1650.
19. Taylor CR, Anderson RR: Ineffective treatment of refractory melasma and postinflammatory hyperpigmentation by Q-switched ruby laser. J Dermatol Surg Oncol 1994, 20:592–597.
20. Tse Y, Levine VJ, McClain SA, Ashinoff R: The removal of cutaneous pigmented lesions with the Q-switched ruby laser and the Q-switched neodymium:yttrium-aluminum-garnet laser. A comparative study. J Dermatol Surg Oncol 1994, 20:795–800.
21. Jang WS, Lee CK, Kim BJ, Kim MN: Efficacy of 694-nm Q-switched ruby fractional laser treatment of melasma in female Korean patients. Dermatol Surg 2011, 37:1133–1140.
22. Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR: Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med 2004, 34:436–438.
23. ALEXIADES-ARMENAKAS MR, DOVER JS, ARNDT KA: Fractional laser skin resurfacing. J Drugs Dermatol 2012, 11:1274–1287.
24. Pandya AG, Hyynas LS, Bhore R, Riley FC, Guevara L, Grimes P, Nordlund JJ, Rendon M, Taylor S, Gottschalk RW, Agim NG, Oronone JP: Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol 2011, 64:78–83.
25. Anderson RR, Parrish JA: Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983, 220:524–527.
26. Chan NP, Ho SG, Shek SY, Yeung CK, Chan HH: A case series of facial depigmentation associated with low fluence Q-switched 1,064 nm Nd:YAG laser for skin rejuvenation and melasma. Lasers Surg Med 2010, 42:712–719.
27. Kauvar AN: Successful treatment of melasma using a combination of microdermabrasion and Q-switched Nd:YAG lasers. Lasers Surg Med 2012, 44:117–124.
28. Sim JH, Park YL, Lee JS, Lee SY, Choi WB, Kim HJ, Lee JH: Treatment of melasma by low-fluence 532 nm Q-switched Nd:YAG laser. J Dermatolog Treat 2013, epub ahead of print.
29. Zhou X, Gold MH, Lu Z, Li Y: Efficacy and safety of Q-switched 1,064 nm neodymium-doped yttrium aluminium garnet laser treatment of melasma. Dermatol Surg 2011, 37:962–970.
30. Chang CJ, Kou CS: Comparing the effectiveness of Q-switched ruby laser treatment with that of Q-switched Nd:YAG laser for ocudermal melanosis (Nevoid of Ota). J Plast Reconstr Aesthet Surg 2011, 64:339–345.
31. Lee GY, Kim HJ, Whang KJ: The effect of combination treatment of the recalcitrant pigmented disorders with pigmented laser and chemical peeling. Dermatol Surg 2002, 28:1120–1123. discussion 1123.
32. Toulaki A, Galimberti MG, Pellacani G, Bencini PL: Combination of fractional erbium-glass laser and topical therapy in melasma resistant to triple-combination cream. J Dermatolog Treat 2012, epub ahead of print.

Cite this article as: Hilton et al.: Treatment of melasma in Caucasian patients using a novel 694-nm Q-switched ruby fractional laser. European Journal of Medical Research 2013 18:43.

Submit your next manuscript to BioMed Central and take full advantage of:
- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

doi:10.1186/2047-783X-18-43